

Magle Group today announces a change in executive leadership

By mutual agreement with the Board of Directors, Justin Pierce has stepped down from his position as Chief Executive Officer, with effect as of the date of this announcement. The decision has been taken for personal and health reasons, following the successful completion of the Company's buy-and-build and strategic integration phase.

During his tenure, Justin Pierce led Magle Group through a period of significant transformation, including the execution of multiple acquisitions, the integration of operations, and the establishment of a consolidated platform to support future growth. The Board and Justin Pierce concur that the integration phase has now been successfully concluded and that this represents an appropriate juncture for a leadership transition as the Company enters its next phase of execution.

Stig Løkke Pedersen, Chairman of the Board, commented:

"Justin has led Magle Group through an extensive buy-and-build and integration period with strong commitment and professionalism. On behalf of the Board, I would like to thank him for his contributions and constructive collaboration, and we wish him every success in his future endeavours."

Justin Pierce commented:

"Following an intensive period focused on building and integrating the Group, I have agreed with the Board that this is an appropriate time for a transition. I appreciate the Board's support and the professional manner in which this process has been conducted. I would also like to thank my colleagues across the Group for their commitment and collaboration."

With immediate effect, Aaron Wong, currently Chief Financial Officer of Magle Group, has been appointed Interim Chief Executive Officer. This appointment is intended to ensure continuity of leadership and day-to-day operations while the Board undertakes an evaluation of the Company's longer-term leadership requirements.

Magle Group has experienced strong growth in recent years, accompanied by increased operational and organisational complexity. The Board believes that this leadership transition positions the Company well to advance into its next phase of development and execution. The Board remains confident in Magle Group's strategy, financial position, and growth prospects, and confirms that the Company's strategy, financial targets, and operational priorities remain unchanged.

Contact Stig Løkke Pedersen

Stig Løkke Pedersen, Chairman, phone +45 40864151, slp@stigloekkepedersen.dk

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-02 13:03 CET.

Attachments

[Magle Group today announces a change in executive leadership](#)